Abstract
Background: Multiple sclerosis (MS) is a demyelinating disease of the central nervous system. Interferon-beta (IFN-β) was the first disease modifying drug to be approved for the treatment of MS. Some MS patients treated with IFN-β develop antibodies to the drug. Anti-IFN-β antibodies can reduce both bioactivity and clinical efficacy of IFN-β. The objective of this study was to develop an enzyme-linked immunosorbent assay (ELISA) method for the measurement of anti-IFN-β antibodies in MS patients treated with CinnoVex (a recombinant Interferon beta 1-a). Methods: An Indirect ELISA protocol was developed and validated for the measurement of anti-IFN-β antibodies. Sera were studied for anti-IFN-β antibodies from 40 healthy individuals and 42 MS patients treated with CinnoVex for at least 6 months. Findings: Patients were considered positive for Anti-IFN-β antibodies, if they had a positive sample with an optical density of more than 1.2. Anti-IFN-β antibodies were found in 12 MS patients treated with CinnoVex. 31.1% of MS patients treated with CinnoVex developed anti-IFN-β antibodies. Conclusion: ELISA is a simple, fast and inexpensive test for the assessment of anti-IFN-β antibodies in MS patients treated with IFN-β.
Original language | English (US) |
---|---|
Pages (from-to) | 1481-1491 |
Number of pages | 11 |
Journal | Journal of Isfahan Medical School |
Volume | 30 |
Issue number | 207 |
State | Published - Dec 2012 |
Externally published | Yes |
Keywords
- Antibodies
- Enzyme-linked immunosorbent assay
- Interferon beta 1a
- Multiple sclerosis
ASJC Scopus subject areas
- General Medicine